following a full submission assessed under the end of life and orphan medicine process:
glofitamab (Columvi®) is accepted for use within NHSScotland.
Indication under review: as monotherapy for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy.
In a phase I/II open-label study, 40% of patients treated with glofitamab who had R/R DLBCL after two or more lines of systemic therapy had a complete response.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.
Medicine details
- Medicine name:
- glofitamab (Columvi)
- SMC ID:
- SMC2614
- Indication:
As monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B‑cell lymphoma (DLBCL), after two or more lines of systemic therapy.
- Pharmaceutical company
- Roche
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 10 June 2024